Track BriaCell Therapeutics Corp. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

BriaCell Therapeutics Corp. BCTX · Stock Open BriaCell Therapeutics Corp. in new tab

3.39 USD
EPS
-6.97
P/B
1.80
ROE
-214.79
Beta
1.66
Loading chart...
Key Metrics
Earnings dateOct. 28, 2026
EPS-6.97
Book Value1.88
Price to Book1.80
% Insiders0.141%
Estimates
Forward P/E-8.69
Forward EPS-0.39

DCF valuation

Model fair value for BriaCell Therapeutics Corp. (BCTX)
Result
Sign in to run the valuation for BCTX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

BriaCell Therapeutics Corp. Logo BriaCell Therapeutics Corp. Analysis (BCTX)

Canada Health Care Official Website Stock

Is BriaCell Therapeutics Corp. a good investment? BriaCell Therapeutics Corp. (BCTX) is currently trading at 3.39 USD.

Earnings Schedule: BriaCell Therapeutics Corp. is expected to release its next earnings report on Oct. 28, 2026. The market consensus estimate for Forward EPS is -0.39.

Investor FAQ

Does BriaCell Therapeutics Corp. pay a dividend?

No, it does not currently pay a dividend.

What asset class is BriaCell Therapeutics Corp.?

BriaCell Therapeutics Corp. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Oct. 28, 2026. The company currently has a trailing EPS of -6.97.

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Exchange Ticker
NMS (United States) BCTX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Dec. 3, 2014 0.307
Jan. 2, 2020 1:300
Jan. 29, 2025 1:15
Aug. 25, 2025 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion